“International Conference on Blood Disorders and Haematology 2017” organized by Clyto Access during 21 – 22 September 2017 in San Francisco, USA. The Conference is intended to providing an international platform for the exchange of knowledge on vast area of Blood Disorders and Haematology. Blood cancer incidences, has high unmet medical necessities and demand for better therapeutics, which is considered as a some major factors behind growth of US blood cancer market segment. US Food and Drug Administration (USFDA) has taken initiatives to support the growth of cancer drugs market by providing pre-market approval to the drugs, which are in the clinical phase, thus, accelerating the clinical development. Several innovative therapeutics are at different stages of clinical trials which would be introduced in coming years.
Haematology conference 2017 is providing an international platform to discuss about the screening of novel target-based drug discovery in Haematological malignancy, enrichment of Haematopoietic stem cells function in blood disorders

to discuss new therapeutic strategy for the treatment of Chronic Myelogenous Leukemia (CML), MyeloFibrosis (MF) and Acute Lymphoblastic Leukemia (ALL).

The conference is inviting participants to discuss on Molecular alterations in bone marrow mesenchymal stromal cells in blood disorders and characterisation of specific Biomarkers in blood disorders.

Haematology conference 2017 is a platform to share knowledge and research work on leukemias of prenatal origin and the specific diagnostic testing methods available in laboratories.

Also, the significant discussion on Chimeric antigen receptor (CAR) immunotherapy, TKI- based therapy and clinical manifestations in blood disorders.